Ultrahigh nanostructured drug payloads from degradable mesoporous silicon aerocrystals.

Porous silicon has found increased attention as a drug delivery system due to its unique features such as high drug payloads, surface area and biodegradation. In this study supercritical fluid (SCF) assisted drying of ultrahigh porosity (>90%) silicon particles and flakes was shown to result in much higher mesopore volumes (~4.66 cm3/g) and surface areas (~680 m2/g) than with air-drying. The loading and physical state of the model drug (S)-(+)-Ibuprofen in SCF dried matrices was quantified and assessed using thermogravimetric analysis, differential scanning calorimetry, UV-Vis spectrophotometry, gravimetric analysis, gas adsorption and electron microscopy. Internal drug payloads of up to 72% were achieved which was substantially higher than values published for both conventionally dried porous silicon (17-51%) and other mesoporous materials (7-45%). In-vitro degradability kinetics of SCF-dried matrices in simulated media was also found to be faster than air-dried controls. The in-vitro release studies provided improved but sustained drug dissolution at both pH 2.0 and pH 7.4.

Engineering and manufacturing of pharmaceutical co-crystals: a review of solvent-free manufacturing technologies.

Design and synthesis of pharmaceutical cocrystals have received great interest in recent years. Cocrystallization of drug substances offers a tremendous opportunity for the development of new drug products with superior physical and pharmacological properties such as solubility, stability, hydroscopicity, dissolution rates and bioavailability. It is now possible to engineer and develop cocrystals via 'green chemistry' and environmentally friendly approaches such as solid-state synthesis in the absence of organic solvents. In addition, significant efforts have been directed towards computational screening, cocrystal manufacturing in a continuous manner and real-time monitoring for quality purposes by using various analytical tools. Pharmaceutical cocrystals are not fully exploited yet and there is a lot of ground to cover before they can be successfully utilized as medical products.

One-step continuous extrusion process for the manufacturing of solid dispersions.

The purpose of this study was to evaluate the performance of synthetic magnesium aluminometasilicate (MAS) as a novel inorganic carrier in hot melt extrusion (HME) processing of indomethacin (IND) for the development of solid dispersions. A continuous extrusion process at various IND/excipient blend ratios (20%, 30% and 40%) was performed using a twin-screw extruder. Physicochemical characterization carried out by SEM, DSC, and XRPD demonstrated the presence of IND in amorphous nature within the porous network of the inorganic material for all extruded formulations. Further, AFM and FTIR studies revealed a single-phase amorphous system and intermolecular H-bonding formation. The IND/MAS extrudates showed enhanced INM dissolution rates within 100% been released within 1h. Stability studies under accelerated conditions (40°C, RH 75%) showed that MAS retained the physical stability of the amorphous solid dispersions even at high drug loadings for 12 months.

Diclofenac sodium sustained release hot melt extruded lipid matrices.

Sustained release diclofenac sodium (Df-Na) solid lipid matrices with Compritol® 888 ATO were developed in this study. The drug/lipid powders were processed via cold and hot melt extrusion at various drug loadings. The influence of the processing temperatures, drug loading and the addition of excipients on the obtained dissolution rates was investigated. The physicochemical characterization of the extruded batches showed the existence of crystalline drug in the extrudates with a small amount being solubilized in the lipid matrix. The drug content and uniformity on the tablet surface were also investigated by using energy dispersive X-ray microanalysis. The dissolution rates were found to depend on the actual Df-Na loading and the nature of the added excipients, while the effect of the processing temperatures was negligible. The dissolution mechanism of all extruded formulations followed Peppas-Korsemeyer law, based on the estimated determination coefficients and the dissolution constant rates, indicating drug diffusion from the lipid matrices.

Sustained release solid lipid matrices processed by hot-melt extrusion (HME).

The aim of this work was to develop sustained release solid lipid matrices of diclofenac sodium (Df-Na) processed by hot melt extrusion (HME) and subsequent compression into tablets. Different extrusion processing approaches such as "cold", "hot" and pre-mixed formulations were used to develop the Compritol(®) 888 ATO lipid matrices by altering the extrusion temperatures, drug loading and formulation composition. The extrudates were characterized via a range of techniques such as differential scanning calorimetry (DSC), hot stage microscopy (HSM) and X-ray powder diffraction (XRPD) to identify the drug state within the lipid matrix. Df-Na was found to be either in crystalline or amorphous state depending on the processing conditions. Energy dispersive X-ray (EDX) microanalysis demonstrated excellent drug distribution of Df-Na on the surface of the compressed tablets. The lipid matrices developed by HME provided sustained release of pre-mixed formulations for 12h mainly controlled by diffusion.

Dissolution enhancement of poorly water-soluble APIs processed by hot-melt extrusion using hydrophilic polymers.

The aim of this study was to investigate the efficiency of hydrophilic polymers to enhance the dissolution rate of poorly water-soluble active pharmaceutical ingredients (APIs) processed by hot-melt extrusion (HME). Indomethacin (INM) and famotidine (FMT) were selected as model active substances while polyvinyl caprolactam graft copolymer, soluplus (SOL) and vinylpyrrolidone-vinyl acetate copolymer grades, Kollidon VA64 (VA64) and Plasdone S630 (S630) were used as hydrophilic polymeric carriers. For the purpose of the study, drug-polymer binary blends at various ratios were processed by a Randcastle single screw extruder. The physicochemical properties and the morphology of the extrudates were evaluated through X-ray diffraction (XRD), differential scanning calorimetry (DSC) and scanning electron microscopy (SEM). Increased drug loadings of up to 40% were achieved in the extruded formulations for both drugs. INM and FMT exhibited strong plasticization effects with increasing concentrations and were found to be molecularly dispersed within the polymer blends. The in vitro dissolution studies showed increased INM/FMT release rates for all formulations compared to that of pure APIs alone.

Synthesis of mesoporous silica nanoparticles and drug loading of poorly water soluble drug cyclosporin A.

Mesoporous silica nanoparticles (MSNs) are introduced as chemically and thermally stable nanomaterials with well-defined and controllable morphology and porosity. It is shown that these particles possess external and internal surfaces that can be selectively functionalized with multiple organic and inorganic groups. Silica nano-particles were synthesized by chemical methods from tetraethylorthosilicate (TEOS), methanol (CH3OH) and deionised water in the presence of sodium hydroxide as catalyst at 80°C temperature. The nature and morphology of particles was investigated by scanning electron microscopy (SEM), N2 adsorption/desorption method using BET instrument and X-ray diffraction (XRD). Silica nanoparticles are applicable to a wide range of therapeutic entities from small molecule to peptides and proteins including hydrophobic and hydrophilic entities. Drug loading does not require chemical modification of the molecule; there are no changes in the drug structure or activity after loading and subsequent release of the drug. Thus, well suited to solve formulation problems associated with hydrophobic drugs such as peptide and protein drugs like cyclosporine A. Silica nanoparticles improved the solubility of poorly water soluble drugs and enhanced the absorption and bioavailability of these compounds.

Inclusion of water insoluble drugs in amorphous silica nanoparticles.

Amorphous silica nanoparticles (a-SiNPs) with high surface area and small pore size have been synthesized using a zwitterionic surfactant in acid media. The produced nanoparticles displayed large specific surface area (-850 m2/g) with an average particles size of 45 nm. The loading efficiency was assessed by incorporating three model water insoluble active substances Carbamazepine (CBZ), Ibuprofen (IBU) and Cyclosporin (CyA) via passive loading and it was found to varying from 15-40%. The loaded silica nanoparticles were analyzed using X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC) to investigate the state of the adsorbed active agents. CyA was found to be in amorphous state, IBU was partially crystalline while CBZ was transformed into form I. The dissolution profiles showed rapid release for CBZ while IBU and CyA demonstrated prolonged release for 24 hr. The viability of Caco-2 cells was not affected in the presence of a-SiNPs showing negligible cytotoxicity (85%) at high concentrations up to 15 mg/ml.

Preparation and characterization of ibuprofen solid lipid nanoparticles with enhanced solubility.

Solid lipid nanoparticles (SLNs) loaded with ibuprofen (IBU) were prepared by solvent-free high-pressure homogenization (HPH). The produced SLNs consisted of stearic acid, triluarin or tripalmitin as lipid matrixes and various stabilizers. The produced empty and IBU-loaded SLNs were characterized for particle size stability over 8 months. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) were implemented to characterize the IBU state of freeze-dried SLNs. IBU was found to be in both amorphous and crystalline form within the lipid matrix. The lyophilized powders showed increased dissolution rates for IBU depending on the lipid nature. SLNs were incubated in Caco-2 cells for 24 h showing negligible cell cytotoxicity up to 15 mg/mL.

Development of solid lipid nanoparticles for enhanced solubility of poorly soluble drugs.

Cyclosporine (CyA) solid lipid nanoparticles were prepared by using a solvent free high pressure homogenization process. CyA was incorporated into SLNs that consisted of stearic acid, trilaurin or tripalmitin lipid solid cores in order to enhance drug solubility. The process was conducted by varying lipid compositions, drug initial loading and applied homogenization pressure. The processing temperatures were above the lipid melting points for all formulations. The empty and CyA loaded SLN particles made were characterized for particle size stability over six months. Atomic force microscopy (AFM) and photon correlation spectroscopy (PCS) showed particle sizes ranging from 112-177 nm for empty and 181-215 nm for loaded SLNs each with narrow particle size distributions. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) techniques were used to characterize the CyA state, which was found to be amorphous, within the lipid cores of freeze-dried SLNs. The CyA metastable form showed a profound effect on the drug dissolution rates. SLNs were incubated in Caco-2 cells for 24 hr showing negligible cell cytotoxicity up to 15 mg/ml.

Inclusion of poorly soluble drugs in highly ordered mesoporous silica nanoparticles.

Silica nanoparticles (MSNs) with a highly ordered mesoporous structures (103A) with cubic Im3 m have been synthesized using triblock copolymers with high poly(alkylene oxide) (EO) segments in acid media. The produced nanoparticles displayed large specific surface area (approximately 765 cm(2)/g) with an average particles size of 120 nm. The loading efficiency was assessed by incorporating three major antiepileptic active substances via passive loading and it was found to varying from 17 to 25%. The state of the adsorbed active agents was further analyzed using differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD). Dissolution studies revealed rapid release profiles within the first 3 h. The viability of 3T3 endothelial cells was not affected in the presence of MSNs indicating negligible cytotoxicity.

Chitosan derivatives alter release profiles of model compounds from calcium phosphate implants.

The aim of the current study was to evaluate the impact of chitosan derivatives, namely N-octyl-chitosan and N-octyl-O-sulfate chitosan, incorporated in calcium phosphate implants to the release profiles of model drugs. The rate and extent of calcein (on M.W. 650 Da) ED, and FITC-dextran (M.W. 40 kDa) on in vitro release were monitored by fluorescence spectroscopy. Results show that calcein release is affected by the type of chitosan derivative used. A higher percentage of model drug was released when the hydrophilic polymer N-octyl-sulfated chitosan was present in the tablets compared with the tablets containing the hydrophobic polymer N-octyl-chitosan. The release profiles of calcein or FD from tablets containing N-octyl-O-sulfate revealed a complete release for FD after 120 h compared with calcein where 20% of the drug was released over the same time period. These results suggest that the difference in the release profiles observed from the implants is dependent on the molecular weight of the model drugs. These data indicate the potential of chitosan derivatives in controlling the release profile of active compounds from calcium phosphate implants.

Enhanced dissolution of oxcarbazepine microcrystals using a static mixer process.

The purpose of this study was to form micronized powders of Oxcarbazepine (OXC), a poorly water-soluble drug, using a static mixer technique to enhance the dissolution rate. Controlled precipitation was achieved injecting the organic OXC solution rapidly into an aqueous methylcellulose (MC) protective solution by means of a static mixer thus providing turbulent and homogeneous mixing. Furthermore, a factorial design was implemented for data analysis. The physicochemical properties of the freeze-dried dispersions were evaluated by differential scanning calorimetry (DSC), infrared spectroscopy (FTIR) and X-ray diffraction (XRD). Drug microcrystals showed a narrow size distribution with approximately 2 microm mean particle size and high drug loading. DSC and FTIR studies revealed that the drug remained in crystalline state and no drug-polymer interaction occurred. The dissolution studies showed enhanced dissolution of OXC microcrystals compared to the pure drug. The static mixer technique was proved capable for micro-sized polymeric particles. This is an inexpensive, less time consuming and fully scalable process for development of poorly soluble drugs.

Stable carbamazepine colloidal systems using the cosolvent technique.

The aim of this paper was to prepare stable carbamazepine nanosuspensions containing 10mg/ml drug concentration by screening different polymers. Stable formulations were created by the cosolvent technique with polyethylene glycol (PEG-300) and water as the cosolvents. Rapid growth of long needle shaped CBZ crystals was observed in the absence of polymer. The presence of hydroxypropyl methylcellulose (HPMC) or methylcellulose (MC) inhibited crystal growth and the mean particle sizes were in the range 10-20 nm. Simultaneous presence of HPMC and polyvinylpyrrolidon (PVP PF17) polymers in CBZ suspensions enhanced the overall stability of the formulations. The additional stability improvement was attributed to the interaction between the polymers by the formation of hydrogen bonds. Suspension stability was evaluated over 5 months where the particle size remained constant. FT-Raman studies showed the existence of form I within the stable CBZ suspensions.

Nano- and micro-particulate formulations of poorly water-soluble drugs by using a novel optimized technique.

A novel technique for the production of nano- and micro-particulate formulations of poorly water-soluble drugs has been developed. This technique involves the use of static mixer elements to provide fast precipitation by continuous turbulent mixing of two liquid flows, an aqueous phase and an organic phase, respectively. The objective of this study was to develop the mixer technique by investigating the influence of the element number on the particle size of the resulting dispersions. Four model active pharmaceutical ingredients (APIs) with a variety of polymers, lipids or surfactants underwent intensive mixing and the final suspensions showed a narrow size distribution. Parameters such as the flow rate and the temperature of the precipitated organic-aqueous phases were also significant in the reduction of particle size. Further development of the mixing technique led to reproducible and stable formulations with minimal excipient amounts. These formulations were spray- or freeze-dried to improve stability.

A polarographic methodology for continuous non-destructive monitoring of drug release from liposomes.

A simple methodology based on the differential pulse polarography (DPP) was developed for non-destructive monitoring of drug release from liposomes. The methodology was also capable of determining not only the released material that remained free in the liposomal suspension but also the amount of the drug which was eventually adsorbed on the vesicles surface after its release from the liposomes. Based on this methodology the release kinetics of encapsulated chlorothiazide in 5 mg ml(-1) DRV liposomes was studied at 37 degrees C at pH 7.4. The results were compared to those obtained by centrifuging the DRV sample and measuring the free drug in the supernatant solution with UV-spectroscopy. Approximately 70% of the initially encapsulated drug were released within 24 h of which ca. 46% were subsequently adsorbed on vesicles' surface.

Quantitative determination of the non-entrapped chlorothiazide in the presence of liposomes using differential pulse polarography.

Differential Pulse Polarography (DPP) was used for the quantitative determination of the free and adsorbed (non-entrapped) chlorothiazide (CHT) in the presence of liposomes. It was found that CHT polarographic signal depends both on the concentration of multilamelar (MLV) liposomes, due to its adsorption on the liposomal surface, and on their size. Calibration plots of CHT concentration versus current density, at pH 7.4, in the presence of different liposomes concentrations were constructed. Based on these curves the non-entrapped chlorothiazide was determined. Results were compared to those obtained from the application of conventional procedure i.e. chromatographic separation of CHT from liposomes followed by UV spectrophotometric determination. Both techniques were found to be comparable with respect to their accuracy, with a relative error of 0.47%. Determination of the drug using DPP was faster.